PPARG and Behcet disease: Furthermore, our SPIED/CMAP analysis predicts that further disease-modifying effects could be achieved by combinatorial approaches that target PPAR-γ and neurotransmitter signalling, such as the α-1 adrenergic receptor antagonist phenoxybenzamine91, and the calcium channel antagonist nifedipine, which has been used in a small cohort study with BD patients92.